biophytis

LIVE HEALTHIER LONGER

AGM
April 26, 2021

Forward Looking Statements

All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for Biophytis SA (the “Company”) and its products, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements.

By their nature, forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and other risks discussed in the Company’s registration statement on Form F-1 and other reports filed with the Securities and Exchange Commission (the “SEC”), which are available for review at http://www.sec.gov/.

Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to publicly update or review such statements to reflect events or circumstances after the date of this presentation, except as required by law.

Agenda

1	Result AGM April 26, 2021 First Call
2	2020 Key achievements
3	Clinical pipeline update
4	Upcoming milestones and outlook

AGM Results

- Biophytis' combined AGM was called today behind closed doors, due to the COVID-19 pandemic.

- **The shareholders taking part in the vote owned collectively 21 736 509 shares, or 19.11% of the share capital, and 19.46% of the voting rights.**

- The 20% quorum necessary for holding an ordinary AGM on first call and the 25% quorum necessary for holding an extraordinary General Meeting on first call have not been reached.

- The AGM is adjourned to a further date in the coming weeks.

Biophytis is a clinical-stage biotechnology company specialized in age-related diseases

Our mission

- **Prevent disabilities** (muscular, respiratory and vision) and increase **health span** for patients suffering from **age-related diseases.**
- Our small molecules are aimed at stimulating **biological resilience and are developed through a drug discovery platform based on a reverse pharmacology approach.**

COVID-19 & Neuromuscular diseases

Drug candidate **Sarconeos (BIO101)** in clinical development for:

- **COVID 19: Phase 2-3**

  Respiratory failure in hospitalized patients with SARS-Cov-2 infection
- **Sarcopenia: Phase 2**

  An age-related degeneration of skeletal muscle
- **Duchenne's Muscular Dystrophy (DMD): Phase 1-2-3**

  A rare pediatric genetic neuromuscular disease

Retinal diseases

- Drug candidate **Macuneos (BIO201)** in preclinical development for diseases of the retina, such as dry **Age-related Macular Degeneration** (AMD) and Stargardt disease,

2020 was a transformational year for Biophytis with great operational and financial performance

Clinical Achievements

Launch of the new COVA study – COVID-19

- Part 1 first interim analysis achieved (50 patients) with positive DMC review in Q1 2021
- Part 2 started with 97 patients recruited in March. The second interim analysis is expected before end Q2 2021
- Top line results for the full study are expected Q2 2021

Completion of SARA-INT study recruitment - Sarcopenia

- Treatment completed for the last patient in the Phase 2 in December 2020.
- Top-line results expected in Q2 2021

IND Approval to start MYODA - DMD

- US IND & Belgium authorization obtained
- Study to start by H1 2021 depending on the evolution of the pandemic

Financial achievements

- Successful completion of four private placements, significantly strengthening financial resources
- Total cash and cash equivalents and other current financial assets of €18.8 million as of December 31, 2020 – an increase of €12 million compared to December 31, 2019
- Additional €13.5 million net proceeds from Nasdaq IPO in Q1 2021

Our clinical pipeline is progressing and expanding since last year

Candidate	Indication	Program
Sarconeos (BIO101)	Covid-19	COVA
	Sarcopenia	SARA
	DMD	MYODA
Macuneos (BIO201)	Dry AMD	MACA
	Stargardt	

- Second generation drug candidates, BIO103 and BIO203, are life-cycle extension candidates in the preclinical Phase

SORBONNE UNIVERSITÉ
CRÉATEURS DE FUTURS DEPUIS 1257

INSTITUTE OF MYOLOGY

INSTITUT DE LA VISION
PARIS

Biophytis

Sarconeos (BIO101) is believed to activate MAS receptor, a key factor for muscle and respiratory functions

- MAS receptor: a key component of the Renin-Angiotensin System (RAS)
- Triggers two important downstream signaling-pathways in myocytes:



PI3K/AKT/mTOR: Increases **protein synthesis,** preserving muscle mass and increasing **muscle strength**

AMPK/ACC **Stimulates energy production**, increasing muscle strength and **mobility**

Sarconeos (BIO101) for respiratory failure in COVID-19

- SARS-CoV-2 uses ACE2 to penetrate the lungs destabilizing RAS system and causing respiratory failures
- Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS system



The COVA study in COVID-19 is now in clinical phase 3

- iDMC recommends the continuation of part 2 recruitment
- More than 97 patients enrolled as of March in 28 clinical centers
- Second interim analysis (155 patients) expected in Q2 2021

Design	Endpoints	Patient Population
• A Phase 2/3 seamless study design • Global, multi-center, double-blind, placebo-controlled group sequential (2 parts), adaptive design • International study including: US, Brazil, France & Belgium • iDMC is monitoring the safety and efficacy of the treatment by running two interim analyses	• Part 1 (N=50): First interim analysis; Obtain safety and tolerability data on Sarconeos (BIO101) • Part 2 (N=155 in total): 2nd interim analysis; promising zone analysis and confirm or reassess sample size • Final analysis Q2 2021 (N= 310 up to 465): Confirmation of the effect of Sarconeos BIO101 in preventing further respiratory deterioration	• Age: 45 years old or over • Hospitalized for severe respiratory symptoms and with proven Covid-19 infection • Patients with respiratory failure not yet requiring mechanical ventilation • Oxygen saturation less than 92%

Product	2020	2021
350 mg b.i.d of Sarconeos (BIO101)	COVA Phase 2-3	

**Independent Data Monitoring Committee*

The SARA-INT Phase 2 sarcopenia trial is nearing completion

- Last patient out in December 2020: 196 participants completed the study over 233 patients initially enrolled with sarcopenia at risk of mobility disability over 22 centers in the US and Belgium
- Topline results in sarcopenia expected in Q2 2021

Design	Endpoints	Patient Population
• Global, double-blind, randomized, placebo-controlled trial: NCT03452488 • Assess safety and efficacy of two doses of Sarconeos (BIO101) administered orally with a meal over 26 weeks, as compared to placebo • Treatment effect on improvement of physical function and on decrease of risk of mobility disability	**Primary** • 400-meter walk test (400MWT) - 0.05 m/s is considered the minimal meaningful change **Key secondary** • Changes in time to rise from a chair. • 400MWT responder analysis • Patient reported outcomes (PRO)	• Age: 65 years old or over • Low mobility measured by Short Performance Physical Battery (SPPB) ≤8 out of 12 • DEXA body composition as measured by ALM/BMI (appendicular lean mass / body mass index) • Able to exercise for 30 minutes per day 5 days per week

Product	2019	2020	2021
175 & 350 mg b.i.d of Sarconeos (BIO101)	SARA-INT Phase 2		

MYODA plans to start Phase 1-2-3 clinical study during H1 2021*

Design	Endpoints	Patient Population
• Global, multicenter, double-blind, placebo-controlled, seamless, Phase 1-2-3 clinical trial • Interim analysis at the end of parts 1 and 2 by iDSMB[1] • Enrollment in the U.S. and EU • Patient advocacy group support • AFM Téléthon in France • Orphan drug designation in US and Europe granted in 2018	• Part 1 (N=18): Safety, tolerability & PK (initial 7 days of dosing of escalating dose of Sarconeos BIO(101)) • Part 2 (N=48): Efficacy of Sarconeos: Respiratory function after dosing for 52 weeks • Part 3 (N= up to 200): Efficacy of Sarconeos BIO(101): Respiratory function after dosing for 52 weeks	• Age: ≥12 years old • Non-ambulatory DMD patients • Patients with respiratory failure not yet requiring mechanical ventilation

Product	2020	2021	2022	2023
Sarconeos (BIO101)	FDA IND and CTA in Belgium granted in 2020	**MYODA Phase 1-2-3**		

1.*Independent Data Safety Monitoring Board*

**Timing is subject to COVID-19- pandemic and availability of financial resources*

Successful US IPO in addition to PIPEs on Euronext totaling €40M

U.S. Initial Public Offering

In February 2021, the Company closed an initial public offering on the NASDAQ (BPTS)

Public offering gross proceeds totaling at closed

$20.1M

(€16.6M)

Oversubscribed

3X

2020 Euronext Financings

The Company successfully closed four private placement transactions

Private placement gross proceeds totaled

€23.4M

Key programs milestones

☑	**COVA**	Started in Belgium, Brazil, France and US
☑	**COVA**	Completion of patient enrollment (Part 1) in January 2021
☑	**COVA**	Interim analysis of Part 1 (50 patients) in Q1 2021
☑	**COVA**	Approvals to start Part 2 in Q1 2021
☐	**COVA**	Interim analysis for Part 2 (155 patients) expected before end Q2 2021
☐	**COVA**	Topline results expected in Q2 2021
☑	**SARA-INT**	(Phase 2) patient enrollment completed in March 2020
☑	**SARA-INT**	Last patient out (LPO) completed in Dec 2020
☐	**SARA-INT**	Topline trial results expected in Q2 2021

2021 Outlook

**Timing is subject to COVID-19- pandemic and availability of financial resources*

The COVA study

- Full results (Part 1 and Part 2) are expected in Q2 2021
- Assuming positive data, subject to any COVID-19 related delays, the Company anticipates applying for EUA in the US and conditional market approvals in EU in Q3 2021.
- Assuming authorizations for the above applications, marketing preparation could start around the end of 2021.*

The SARA -INT study

- Following the last visit of the last patient in December 2020, top-line results of the Phase 2 trial are expected during Q2 2021.
- Depending on Phase 2 results a Phase 3 study could be commenced in 2022*

The MYODA study

- Subject to any COVID-19 related delays, the Company intends to start the Phase 1-2-3 MYODA trial in H1 2021*

CONTACTS:

- Stanislas Veillet – CEO
  stanislas.veillet@biophytis.com
- Evelyne NGUYEN – CFO
  evelyne.nguyen@biophytis.com

Thank you

Investor relations: investors@biophytis.com
Website: www.biophytis.com

biophytis